Takeda expands Phase III ixazomib MM program to Japan
This article was originally published in Scrip
Executive Summary
Takeda has begun enrolling the first patients in Japan into the ongoing TOURMALINE-MM1 Phase III global study with potential Velcade successor ixazomib citrate (MLN9708), to generate data in support of a planned approval filing in the country.